Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01531582 · ClinicalTrials.gov registry record · NA
Minocycline in the Treatment of Angelman Syndrome
A NA study, sponsored by University of South Florida.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT01531582 is a NA study that has completed, run by University of South Florida. The registered enrollment target is 25 participants.
The verdict
NCT01531582, a NA study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
There is mounting evidence to suggest that a treatment for Angelman syndrome is not just possible, but probable. The lack of known molecular targets associated with AS has hampered the development of specific therapeutics. However, a recent surge of potential therapeutics for other disorders associated with cognitive disruption has begun to be used in human clinical trials. The molecular modes of action for many of these new therapeutic agents have correlates to counter the molecular defects observed in AS. One such agent is minocycline (MC), a drug traditionally used as an antibiotic. This compound administered to a mouse model of AS showed a significant decrease in motor deficit and an increase in long term potentiation. The investigators believe a similar result will be observed when minocycline is administered to the AS patient and may lead to the development of an effective AS therapeutic.
Interventions
- DRUG minocycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01531582
The ClinicalTrials.gov registry entry for NCT01531582 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which minocycline is the first listed.
NCT01531582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01531582 about?
NCT01531582 is a clinical study titled "Minocycline in the Treatment of Angelman Syndrome". There is mounting evidence to suggest that a treatment for Angelman syndrome is not just possible, but probable. The lack of known molecular targets associated with AS has hampered the development of specific therapeutics. However, a recent surge of potential therapeutics for other disorders associa...
What is the current status of trial NCT01531582?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2012-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01531582?
The interventions under investigation include: minocycline (DRUG).
Who is sponsoring clinical trial NCT01531582?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.